Report cover image

Contraceptive Drugs Market

Publisher Evolve Business Intelligence
Published Apr 14, 2025
SKU # EVBI19932178

Description

The Contraceptive Drugs Market is projected to reach USD 300.41 billion by 2033, growing from USD 28.10 billion in 2023, with an anticipated compound annual growth rate (CAGR) of 6.67% from 2023 to 2033. This market encompasses global sales of medications designed to prevent pregnancy, including oral contraceptives (birth control pills), injectables, skin patches, and vaginal rings. These contraceptives function through various mechanisms, such as inhibiting ovulation (the release of an egg from the ovary), thickening cervical mucus to impede sperm movement, or altering the uterine lining to prevent the implantation of a fertilized egg.

The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.

Segments covered

By Product Type (Drugs, Devices, Intrauterine Devices (IUDs), Hormonal IUDs, Copper IUDs, Diaphragms, Others)
By End Users (Household, Hospitals, Clinic)

Key players

Bayer AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co. Inc.
Mylan N.V.
Allergan Plc
Agile Therapeutics
GlaxoSmithKline PLC
Johnson & Johnson
Novartis AG

Table of Contents

Chapter 1. Executive Summary
Chapter 2. Scope Of The Study
2.1. Market Definition
2.2. Scope Of The Study
2.2.1. Objectives of Report
2.2.2. Limitations
2.3. Market Structure
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.1.1. Raw End Users Providers
4.1.2. Manufacturing Process
4.1.3. Distributors/Retailers
4.1.4. End-Use Industry
4.2. Porter’s Five Forces Analysis
4.2.1. Threat Of New Entrants
4.2.2. Bargaining Power Of Buyers
4.2.3. Bargaining Power Of Suppliers
4.2.4. Threat Of Substitutes
4.2.5. Industry Rivalry
4.3. Impact Of COVID-19 on the Contraceptive Drugs Market
4.3.1. Impact on Market Size
4.3.2. End-Use Industry Trend, Preferences, and Budget Impact
4.3.3. Regulatory Framework/Government Policies
4.3.4. Key Players' Strategy to Tackle Negative Impact
4.3.5. Opportunity Window
4.4. Technology Overview
12.28. Macro factor
4.6. Micro Factor
4.7. Demand Supply Gap Analysis of the Contraceptive Drugs Market
4.8. Import Analysis of the Contraceptive Drugs Market
4.9. Export Analysis of the Contraceptive Drugs Market
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DROC Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
5.2.4. Challenges
5.3. Patent Analysis
5.4. Industry Roadmap
5.5. Parent/Peer Market Analysis
Chapter 6. Global Contraceptive Drugs Market, By Product Type
6.1. Introduction
6.2. Drugs
6.3. Devices
6.4. Intrauterine Devices (IUDs)
6.5. Hormonal IUDs
6.6. Copper IUDs
6.7. Diaphragms
6.8. Others
Chapter 7. Global Contraceptive Drugs Market, By End User
7.1. Introduction
7.2. Household
7.3. Hospitals
7.4. Clinic
Chapter 8. Global Contraceptive Drugs Market, By Region
8.1. Introduction
8.2. North America
8.2.1. Introduction
8.2.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.2.3. Market Size and Forecast, By Country, 2023-2033
8.2.4. Market Size and Forecast, By Product Type, 2023-2033
8.2.5. Market Size and Forecast, By End User, 2023-2033
8.2.6. US
8.2.6.1. Introduction
8.2.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.2.6.3. Market Size and Forecast, By Product Type, 2023-2033
8.2.6.4. Market Size and Forecast, By End User, 2023-2033
8.2.7. Canada
8.2.7.1. Introduction
8.2.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.2.7.4. Market Size and Forecast, By Product Type, 2023-2033
8.2.7.5. Market Size and Forecast, By End User, 2023-2033
8.3. Europe
8.3.1. Introduction
8.3.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.3.3. Market Size and Forecast, By Country, 2023-2033
8.3.4. Market Size and Forecast, By Product Type, 2023-2033
8.3.5. Market Size and Forecast, By End User, 2023-2033
8.3.6. Germany
8.3.6.1. Introduction
8.3.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.3.6.3. Market Size and Forecast, By Product Type, 2023-2033
8.3.6.4. Market Size and Forecast, By End User, 2023-2033
8.3.7. France
8.3.7.1. Introduction
8.3.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.3.7.3. Market Size and Forecast, By Product Type, 2023-2033
8.3.7.4. Market Size and Forecast, By End User, 2023-2033
8.3.8. UK
8.3.8.1. Introduction
8.3.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.3.8.3. Market Size and Forecast, By Product Type, 2023-2033
8.3.8.4. Market Size and Forecast, By End User, 2023-2033
8.3.9. Italy
8.3.9.1. Introduction
8.3.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.3.9.3. Market Size and Forecast, By Product Type, 2023-2033
8.3.9.4. Market Size and Forecast, By End User, 2023-2033
8.3.11. Rest Of Europe
8.3.11.1. Introduction
8.3.11.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.3.11.3. Market Size and Forecast, By Product Type, 2023-2033
8.3.11.4. Market Size and Forecast, By End User, 2023-2033
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.4.3. Market Size and Forecast, By Country, 2023-2033
8.4.4. Market Size and Forecast, By Product Type, 2023-2033
8.12.28. Market Size and Forecast, By End User, 2023-2033
8.4.6. China
8.4.6.1. Introduction
8.4.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.4.6.3. Market Size and Forecast, By Product Type, 2023-2033
8.4.6.4. Market Size and Forecast, By End User, 2023-2033
8.4.7. India
8.4.7.1. Introduction
8.4.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.4.7.3. Market Size and Forecast, By Product Type, 2023-2033
8.4.7.4. Market Size and Forecast, By End User, 2023-2033
8.4.8. Japan
8.4.8.1. Introduction
8.4.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.4.8.3. Market Size and Forecast, By Product Type, 2023-2033
8.4.8.4. Market Size and Forecast, By End User, 2023-2033
8.4.9. South Korea
8.4.9.1. Introduction
8.4.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.4.9.3. Market Size and Forecast, By Product Type, 2023-2033
8.4.9.4. Market Size and Forecast, By End User, 2023-2033
8.4.10. Rest Of Asia-Pacific
8.4.10.1. Introduction
8.4.10.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.4.10.3. Market Size and Forecast, By Product Type, 2023-2033
8.4.10.4. Market Size and Forecast, By End User, 2023-2033
8.5. Rest Of The World (RoW)
8.5.1. Introduction
8.5.2. Driving Factors, Opportunity Analyzed, and Key Trends
8.5.3. Market Size and Forecast, By Product Type, 2023-2033
8.5.4. Market Size and Forecast, By End User, 2023-2033
Chapter 9. Company Landscape
9.1. Introduction
9.2. Vendor Share Analysis
9.3. Key Development Analysis
9.4. Competitor Dashboard
Chapter 10. Company Profiles
10.1. Bayer AG
10.1.1. Business Overview
10.1.2. Government & Defense Analysis
10.1.2.1. Government & Defense – Existing/Funding
10.1.3. Product Portfolio
10.1.4. Recent Development and Strategies Adopted
10.1.5. SWOT Analysis
10.2. Pfizer Inc.
10.2.1. Business Overview
10.2.2. Government & Defense Analysis
10.2.2.1. Government & Defense – Existing/Funding
10.2.3. Product Portfolio
10.2.4. Recent Development and Strategies Adopted
10.2.5. SWOT Analysis
10.3. Teva Pharmaceutical Industries Ltd.
10.3.1. Business Overview
10.3.2. Government & Defense Analysis
10.3.2.1. Government & Defense – Existing/Funding
10.3.3. Product Portfolio
10.3.4. Recent Development and Strategies Adopted
10.3.5. SWOT Analysis
10.4. Merck & Co. Inc.
10.4.1. Business Overview
10.4.2. Government & Defense Analysis
10.4.2.1. Government & Defense – Existing/Funding
10.4.3. Product Portfolio
10.4.4. Recent Development and Strategies Adopted
10.12.28. SWOT Analysis
10.5. Mylan N.V.
10.5.1. Business Overview
10.5.2. Government & Defense Analysis
10.5.2.1. Government & Defense – Existing/Funding
10.5.3. Product Portfolio
10.5.4. Recent Development and Strategies Adopted
10.5.5. SWOT Analysis
10.6. Allergan Plc
10.6.1. Business Overview
10.6.2. Government & Defense Analysis
10.6.2.1. Government & Defense – Existing/Funding
10.6.3. Product Portfolio
10.6.4. Recent Development and Strategies Adopted
10.6.5. SWOT Analysis
10.7. Agile Therapeutics
10.7.1. Business Overview
10.7.2. Government & Defense Analysis
10.7.2.1. Government & Defense – Existing/Funding
10.7.3. Product Portfolio
10.7.4. Recent Development and Strategies Adopted
10.7.5. SWOT Analysis
10.8 GlaxoSmithKline PLC
10.8.1. Business Overview
10.8.2. Government & Defense Analysis
10.8.2.1. Government & Defense – Existing/Funding
10.8.3. Product Portfolio
10.8.4. Recent Development and Strategies Adopted
10.8.5. SWOT Analysis
10.9 Johnson & Johnson
10.9.1. Business Overview
10.9.2. Government & Defense Analysis
10.9.2.1. Government & Defense – Existing/Funding
10.9.3. Product Portfolio
10.9.4. Recent Development and Strategies Adopted
10.9.5. SWOT Analysis
10.10. Novartis AG
10.10.1. Business Overview
10.10.2. Government & Defense Analysis
10.10.2.1. Government & Defense – Existing/Funding
10.10.3. Product Portfolio
10.10.4. Recent Development and Strategies Adopted
10.10.5. SWOT Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us